Quick Answer
Opus Genetics, Inc. reported Operating Income of -$38.60 million for fiscal year 2025.
Opus Genetics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$38.60M | +37.8% |
| 2024 | -$62.07M | -487.7% |
| 2023 | -$10.56M | -158.0% |
| 2022 | $18.23M | +180.3% |
| 2021 | -$22.70M | -13.7% |
| 2020 | -$19.97M | -376.2% |
| 2019 | -$4.19M | +79.6% |
| 2018 | -$20.54M | -18.3% |
| 2017 | -$17.35M | -5.7% |
| 2016 | -$16.41M | +10.1% |
| 2015 | -$18.26M | -37.6% |
| 2014 | -$13.27M | -66.3% |
| 2013 | -$7.98M | -21.3% |
| 2012 | -$6.58M | +59.2% |
| 2011 | -$16.13M | -56.5% |
| 2010 | -$10.31M | -59.4% |
| 2009 | -$6.47M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.31M | -3.8% | +6.7% |
| June 30, 2025 | -$8.91M | -6.9% | +10.3% |
| March 31, 2025 | -$9.93M | -28.8% | -24.0% |
| September 30, 2024 | -$8.01M | -225.4% | +3.8% |
| June 30, 2024 | -$8.33M | -54.5% | -8.0% |
| March 31, 2024 | -$7.71M | -25.7% | -220.7% |
| September 30, 2023 | $6.39M | +240.7% | +218.5% |
| June 30, 2023 | -$5.39M | -9.1% | +12.1% |
- Opus Genetics, Inc. showed an increase of +37.8% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Opus Genetics, Inc.’s operating income has declined by 497.0% (from -$6.47 million to -$38.60 million).
- The most recent figure is from Opus Genetics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: